Investors Seek Answers on Novo Nordisk's Next-Gen Obesity Drug CagriSema
LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation ...
Focus: Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo Nordisk Foundation Will Not Fill Funding Gaps
Novo’s record profit from obesity drugs has given the Foundation a war chest to fund its philanthropic grants, although ...
News & Record15hOpinion
Froma Harrop: Dems need to focus, starting with drug prices
Donald Trump is executing a shock-and-awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...
4NVO : Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. If we consider the specifics of ...
No plan to prop up global health, Novo Nordisk Foundation says, as Trump freezes US aid
The Novo Nordisk Foundation does not plan to step in to prop up a global health sector reeling from a freeze on U.S.-funded ...
The Columbian18h
Harrop: Democrats should focus, start with drug prices
Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in the courts. Some, ...
Opinion
Harrop: Democrats have a winning issue: drug prices
The right-wing argues, as Project 2025 puts it, that government negotiations on Medicare drugs amount to “price controls” that will reduce patient access to new medication. That’s news to the citizens ...